| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4427 |
| filingDate |
2009-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2011-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2011520890-A |
| titleOfInvention |
Oxazolobenzimidazole derivatives |
| abstract |
The present invention is a potentiator of metabotropic glutamate receptors, particularly mGluR2 receptors, and is useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases involving metabotropic glutamate receptors. A certain oxazolobenzimidazole derivative is targeted. The present invention is also directed to pharmaceutical compositions comprising this compound and the use of this compound and composition in the prevention or treatment of such diseases involving metabotropic glutamate receptors. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018199284-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2018199284-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013062079-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7198201-B2 |
| priorityDate |
2008-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |